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We  review  the  international  deﬁnitions  of  endocrine  disruptors  (EDs).
We  discuss  the  association  of  EDs  with  the testicular  dysgenesis  syndrome.
We  discuss  the  pivotal  role  of  potency  in  the  safety  assessment  of  EDs.
We  discuss  additive  effects  of human  simultaneous  exposure  to several  EDs.
We  discuss  whether  human  exposure  to chemical  EDs  poses  a human  health  risk.
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a  b  s  t  r  a  c  t
Endocrine  disruptors  (EDs)  are  substances  that  cause  adverse  health  effects  via endocrine-mediated
mechanisms  in an  intact  organism  or its progeny  or (sub)  populations.  Purported  EDCs  in personal
care  products  include  4-MBC  (UV  ﬁlter)  or parabens  that showed  oestrogenic  activity  in screening  tests,
although  regulatory  toxicity  studies  showed  no adverse  effects  on  reproductive  endpoints.  Hormonal
potency  is the  key issue  of  the safety  of  EDCs.  Oestrogen-based  drugs,  e.g.  the contraceptive  pill or the
synthetic  oestrogen  DES,  possess  potencies  up  to 7 orders  of  magnitude  higher  than  those  of  PCP  ingredi-
ents;  yet,  in utero  exposure  to these  drugs  did  not  adversely  affect  fertility  or sexual  organ  developmentesticular dysgenesis syndrome of  offspring  unless  exposed  to  extreme  doses.  Additive  effects  of  EDs are unlikely  due  to  the  multitude  of
mechanisms  how  substances  may  produce  a hormone-like  activity;  even  after uptake  of different  sub-
stances  with  a similar  mode  of  action,  the  possibility  of  additive  effects  is  reduced  by different  absorption,
metabolism  and  kinetics.  This  is supported  by a number  of  studies  on  mixtures  of  chemical  EDCs.  Overall,
despite  of 20  years  of research  a human  health  risk  from  exposure  to  low  concentrations  of  exogenous
 wea
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It has been understood for a long time that a high consump-
tion of hormonally active plant constituents, such as coumestrol
or daidzein contained in clover, can adversely affect reproduc-
tion in domestic animals, up to induction of permanent infertility
(Lindner, 1976). Therefore, it is not surprising that high doses of
industrial chemicals, such as phthalates, chlorinated compounds
as well as numerous other substances were also found to adversely
affect reproduction in laboratory animals. From the early 1990s to
the present, additional concerns have been raised that other man-
made chemicals, such as phthalates, polychlorinated biphenyls or
alkylphenols may  also affect the reproduction in humans, wildlife
or aquatic organism by disrupting their endocrine functions, e.g.
hormones secreted by human ovaries, testes, thyroid or other
Open access under CC BY-NC-ND license.organs (Nilsson, 2000; Safe, 1997, 2004). Thus a novel category of
potentially hazardous substances, endocrine disruptors or endocrine
modulators was  born, although the exact deﬁnition of the meaning
of these terms is still debated and somewhat unclear (Foster and
-NC-ND license.
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gzarian, 2008). Indeed, the European Union, the WHO  and the
S EPA employ slightly different deﬁnitions thereby adding to the
readth of interpretational room for any data generated. Special
oncerns have been raised by some scientists and environmen-
al activists that human exposure to hormonally-active ingredients
sed in personal care products/cosmetics with potential hormonal
ctivity, such as parabens, phthalates or certain ultraviolet ﬁlters,
ay  affect human endocrine systems and pose a risk to human
ealth (Witorsch and Thomas, 2010). For example, it has been sug-
ested that human exposure, in particular pre-natal exposure of the
uman foetus, to such substances may  affect human semen qual-
ty, produce or contribute to male infertility, birth defects in male
nfants, breast and testicular cancers, obesity and other adverse
ealth effects.
Given that chemicals with potential hormone-like activity,
n particular personal care product ingredients, have a minute
otency when compared with that of actual, mammalian hor-
ones, such as oestradiol, novel hypotheses were developed that
uman exposure to mixtures of a multitude of weakly active
ubstances may  produce additive or even synergistic effects and
et pose a risk to human health (Witorsch, 2002a; Myers et al.,
009). Considering these hypotheses, we attempted to summarise
he present state of knowledge on Endocrine disruptors and to
eview whether ingredients of personal care products/cosmetics
ay  produce adverse human health effects secondary to endocrine
isruption.
. What are “Endocrine disruptors”?
The Endocrine system is the term for multiple and diverse
ormonal systems in the mammalian organism, such as thy-
oid hormones, hormones originating from the pancreas, ovaries,
estes, adrenals or the brain. There have been a number of
eﬁnitions of what is an “Endocrine disruptor” (ED). The most
ommonly agreed are the following: An ED is an exogenous
ubstance that causes adverse health effects in the intact organ-
sm or its progeny, secondary/consequent to changes in endocrine
unction“(Weybridge, 1996). A similar deﬁnition has been cho-
en by the World Health Organisation’s International Program on
hemical Safety: An endocrine disrupter is an exogenous substance
r mixture that alters function(s) of the endocrine system and con-
equently causes adverse health effects in an intact organism, or its
rogeny, or (sub)populations (WHO/IPCS, 2002). A joint expert group
f the German Bundesamt fuer Risikobewertung (BfR) and UK
ealth authorities (UK-BfR) regulatory expert group proposed an
dentical deﬁnition: An ED is an exogenous substance or mixture that
lters function(s) of the endocrine system and consequently causes
dverse health effects in an intact organism, or its progeny or (sub)
opulations (BfR, 2011). The most recent deﬁnition issued by the
U is that an ED is an exogenous substance that causes adverse health
ffects in an intact organism, or its progeny, secondary to changes in
ndocrine function (EU, 2012); this is also consistent with the recent
eﬁnition by the European Food Safety Agency (EFSA, 2013). The US
PA deﬁned EDC as follows: Endocrine disrupting chemicals (EDCs)
ave been deﬁned as exogenous agents that interfere with the pro-
uction, release, transport, metabolism, binding, action, or elimination
f the natural hormones in the body responsible for the maintenance
f homeostasis and the regulation of developmental processes (EPA,
012).
It is important to note that all major international deﬁnitions
tipulate that an EDC must cause adverse effects via an endocrine-
ediated mechanism in an intact organism. A common deﬁnition
f what constitutes an adverse effect has been proposed by the
fR/UK expert group, the WHO  IPCS, ECETOC and independent
uthors (BfR, 2011; WHO/IPCS, 2002; ECETOC, 2009; Lewis et al.,tters 223 (2013) 295– 305
2002). All current deﬁnitions agree that the deﬁnition of an
“adverse effect” means toxicity, i.e. pathology or functional impair-
ment. Therefore, only a substance that produces toxicity in an intact
organism via a hormonal or hormone-like mechanism represents
a genuine ED.
Often substances have been reported to be ED based on the
results of screening tests. Indeed, a considerable number of in vitro
(sub-cellular or cellular) and in vivo (animal) screening tests
for hormone-like activities of substances have been developed
(Borgert et al., 2011). However, these tests were established for
the purpose of screening, i.e. in order to prioritise toxicological
testing of substances that may  possess hormonal activities. Given
that screening tests do not identify toxicity, they cannot determine
whether a substance is an ED or not. Screening tests do not even
assure that a substance will produce a hormonal activity in humans
or other organisms; they merely suggest that the test substance
may have such a potential. Therefore, when a substance produces
changes in hormone-related parameters in screening tests, this
means that the test substance has a biological activity, but it does
not mean that it is toxic or is an ED. This view is also supported
by a recent position of the European Food Safety Agency (EFSA,
2013). Indeed, there are more than a thousand natural or synthetic
substances that have been found to be positive in screening assays
and to possess weak hormone-like activities without causing actual
toxicity at the individual or the population level. Weak hormonal
activity can be advantageous, detrimental or neutral for the organ-
ism. To illustrate this: a change in room temperature, a meal or
daylight may  induce changes in circulating levels of hormones, such
as thyroid hormones, insulin or melatonin, respectively (Foster and
Agzarian, 2008). This does not mean that these innocuous factors
should be considered to be EDs.
Similarly, our food is full of hormonally active substances: for
example, soy contains substances (isoﬂavones) that possess pow-
erful oestrogenic activity in screening assays, which have been
shown to produce adverse reproductive effects in animal toxicity
studies (Delclos et al., 2001; McClain et al., 2007). Thus, by deﬁni-
tion, soy isoﬂavones, such as genistein, are genuine EDs. However,
isoﬂavones do not produce oestrogenic effects in humans or non-
human primates at dietary levels (Cline et al., 2001). Moreover,
Asian populations with a high dietary intake of soy or soy-based
food tend to have lower cancer rates of reproductive organs or
breast, when compared with European or US populations (Peeters
et al., 2003), but do not present an increased incidence of lower
sperm count or TDS (testicular dysgenesis syndrome). It has been
suggested that phytoestrogens may  be useful for the prevention of
breast and other cancers (Humphrey, 1998; Mense et al., 2008).
Natural oestrogens or similar hormone-like substances are con-
tained in clover, hops, Brussels sprouts, beer, wine, walnuts, linseed
and many other plant foods (Kurzer and Xu, 1997). It has been
known for centuries or longer that grazing sheep or cattle on clover
may  result in infertility, the so-called clover disease.  Today, we know
that this is due to coumestrol and daidzein, natural constituents of
clover and natural contraceptives (Lindner, 1976; Oellermann et al.,
1987). Given that clover or soy phyto-oestrogens have oestrogenic
activity in vitro and been shown to adversely affect reproduction
in animals, they should be considered genuine EDs – although,
at normal concentrations present in animal feed or human food,
there is no evidence that they pose a risk to health. A human
health risk from soy isoﬂavones is also reduced by the fact that
humans have a greater ability to than laboratory rodents to detoxify
ingested isoﬂavones via glucuronidation in the gut wall or the liver
(Pritchett et al., 2008; Setchell et al., 2008; Rozman et al., 2006).
However, these examples demonstrate that mammalian organ-
isms do not differentiate between natural and synthetic substances
with respect to potential adverse effects. Overall, hormonal activ-
ity of a substance represents a biological activity or a mechanism
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hat can be good, bad or neutral for the intact organism. Hor-
onal activity on its own has little to do with hazard (toxicity)
r even less suggests a health risk for the intact organism unless
t leads adverse outcomes, for example carcinogenic, reproductive,
r developmental effects that are routinely considered in reaching
egulatory decisions (Dekant and Colnot, 2013; Testai et al., 2013;
PA, 2012).
. Is there an association of endocrine disruptors and
reast cancer?
Certain persistent organochlorine substances, such as pesticides
DDT) or polychlorinated biphenyls (PCB), have been shown to
ave a weak potential for hormonal activity. These substances were
ever used in Personal Care Products and have been banned in
he US, Europe or Japan for more than 30 years, although declin-
ng residues continue to be present in the environment. It has
een suggested that residues of these substances in the human
rganism combined with their hormonal activity may  play a role
n the aetiology of breast cancer. Indeed, in 1992, US researchers
eported elevated levels of PCBs and DDT in a relatively small group
f women with breast cancer; subsequent US studies suggested a
light association between breast cancer and elevated serum DDT,
ut not serum PCB, levels (Krieger et al., 1994; ACSH, 1999). How-
ver, follow-up studies on a large number of US breast cancer
atients found no correlation between the human body burden of
rganochlorine substances and breast cancer. Subsequent ofﬁcial
S reviews of the association of breast cancer, endometrial can-
er and endometriosis with organochlorine residues concluded that
o such relationship could be supported by the existing evidence
Ahlborg et al., 1995; Safe, 1997).
In 2004, a study reporting paraben residues in human breast
umour tissues re-opened the media attention and subsequent
ebate about a possible link between endocrine disruption and
reast cancer. Given that some long-chain parabens possess a very
eak potential for hormonal activity, the authors of the study
uggested that parabens contained in underarm deodorants may
igrate into the breast and therefore may  have a causal role in
he aetiology of breast cancer (Darbre et al., 2004). However, that
tudy had serious weaknesses: the detected paraben residues were
inute (in the range of nanograms per gram of tissue), the study
id not investigate paraben levels in healthy tissues and there is
o known direct transport mechanism of externally applied under-
rm substances into the breast. Finally, the study detected the same
arabens in tumours and blank solvents that were used for tissue
xtraction. Moreover, the authors failed to notice that deodorants
o not contain parabens since they require no preservatives due
o their high content of aluminium. The study and its claims were
ejected as ﬂawed by a number of experts and international health
uthorities who concluded that there is no scientiﬁc evidence link-
ng underarm deodorants or parabens with breast cancer (Witorsch
nd Thomas, 2010). This view is supported by the results of a
arge epidemiological investigation that showed no evidence for
n increased risk of breast cancer and underarm antiperspirant use
Mirick et al., 2002). Nevertheless, an urban legend was born.
Indeed, long-chain parabens (butylparaben, propylparaben)
ossess extremely weak estrogenic potencies, i.e. about 10,000-
o 1,000,000 lower than that of oestradiol or synthetic hormones,
uch as ethinylestradiol, an active agent of contraceptive drugs
Routledge et al., 1998; Golden et al., 2005; CIR, 2008). Yet, the
uman contraceptive pill is used daily, chronically, and contains
arge doses of highly potent oestrogens and other hormones. How-
ver, use of the contraceptive pill has not been associated with a
igniﬁcant increase in the risk of breast cancer. It is therefore sci-
ntiﬁcally implausible how the minute activity of parabens couldtters 223 (2013) 295– 305 297
pose a risk to human health, particularly when they are contained
in low concentrations in products that are applied to human skin.
In this context it should also be mentioned that the incidence of
breast cancer in the US and other industrialised countries has been
stable since the 1980s, which is also inconsistent with the alleged
human exposure to EDCs (SEER, 2010; Ahlborg et al., 1995; Safe,
1997).
3. The hypothesis of the “Testicular dysgenesis syndrome”
(TDS)
A current hypothesis has suggested that, in modern industrial
societies, human male fertility is declining, whereas the incidence
of diseases or birth defects of the male reproductive system is
increasing. The hypothesis that human sperm count is declin-
ing whereas the incidence of testicular cancer, cryptorchidism
(undescended testis) and hypospadias (abnormally placed urethral
opening at the underside of the penis) is increasing and that these
changes are associated with human exposure to hormonally active
chemicals. The hypothesis was  popularised in 1992, when a group
of Danish researchers reported a 50% decrease in sperm count
for the period of 1938–1992 (Carlsen et al., 1992), although that
study had signiﬁcant weaknesses (Handelsman, 2001; Fish, 2000
and 2008). In the meantime, this hypothetical syndrome has been
named the “Testicular dysgenesis syndrome” (TDS). It postulates
that, in Western industrialised countries a) human male fertility,
in particular sperm count, has declined and continues to decline,
b) the incidence of human testicular cancer is increasing, c) the
incidence of cryptorchidism and d) hypospadias in newborn male
infants has increased (Thorup et al., 2010). An additional hypothesis
is that the increased incidence in the TDS may  be due to chemical
EDC in the human environment.
First, it should be realised that sperm count is not equal to male
fertility. It is a common fallacy that male fertility can be measured
by counting sperm. Sperm count/output is actually a surrogate vari-
able for male fertility, but not necessarily a good one (Handelsman,
2001). For example, studies in Sweden (Akre et al., 1999; Scheike
et al., 2008) or the UK (Joffe, 2000) suggested that human fertil-
ity has increased in the past decades. Second, there is no evidence
for a general decline in sperm count (Saidi et al., 1999; Fish, 2000,
2008; Thorup et al., 2010; Itoh et al., 2001; Handelsman, 2001; Safe,
2004, 2005; Greim, 2005). Although some studies found a decline
(Carlsen et al., 1992; Rolland et al., 2012), others found an increase
in sperm count (Saidi et al., 1999; Fish, 2008). A recent study, one
of the largest, longest and best-controlled investigations ever per-
formed on this issue, found no decrease, but a slight, but signiﬁcant
increase in the mean sperm count of nearly 5000 Danish mili-
tary recruits over the period of 1996–2010 (some study data ﬁrst
reported by Bonde et al., 2011). Although the results of that study
have been available for several years, the complete study was only
published in 2012 (Jorgensen et al., 2012), possibly in response
to pressure from the scientiﬁc community (Anon., 2011; Wilcox,
2011; Bonde et al., 2011). Nevertheless, a number of far smaller
studies that claimed declining sperm counts were published by the
same researchers – and widely reported by the media.
Clearly, such a “publication bias” distorts the public risk percep-
tion and may  result in conjuring imaginary health risks and disease
associations with exposure to chemicals. Given that current data
suggest that sperm count in Denmark had remained unchanged
or even slightly improved over the past 15 years, this ﬁnding is
now consistent with similar data from Japan, Sweden and the US,
which showed that sperm count has remained stable for the past
20 years (Itoh et al., 2001; Axelsson et al., 2011; Fish, 2008; Saidi
et al., 1999). Here it also should be considered that sperm counts
reported prior to the 1990s must be regarded with great caution due
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o methodological shortcomings and non-standardised methods
Handelsman, 2001; Fish, 2008). Even in industrialised countries
 lack of compliance with standardised sperm morphology/count
ethods was reported as recently as 2012 or 2005 (Mallidis et al.,
012; Riddell et al., 2005). Finally, the notion that prenatal oestro-
en exposure has adverse effects on male fertility has been refuted
y studies on boys born to women exposed to high oral DES
oses during pregnancy. Neither fertility nor sperm output were
dversely affected despite massive in utero oestrogen exposure,
lthough minor urogenital malformations did occur in this popu-
ation (Leary et al., 1984; Handelsman, 2001). It is noteworthy that
here was an approximate 14-fold difference between the highest
nd the lowest clinical dose of DES; reproductive malformations
ere observed only among the offspring of women who received
igh-dose regimens (Borgert et al., 2012).
Moreover, there is no scientiﬁc evidence for a general increase in
he incidence of cryptorchidism or hypospadias in male infants; in
ddition, it has been argued that these two pathologies are caused
y different mechanisms, which cast even more doubt on a com-
on  origin or a common causal agent (Thorup et al., 2010). An
ncreased risk of hpospadias or cryptorchidism appears to be asso-
iated with increasing maternal age and body mass (Fish et al.,
001; McGlynn et al., 2006), whereas a high incidence in hypospa-
ias has also been linked with a maternal low protein or vegetarian
iets during pregnancy (Akre et al., 2008; North and Golding, 2000).
n the other hand, there appears to be an increase in the incidence
n testicular cancer in some Western countries, although the inci-
ence in other industrialised countries and regions, such as Asia,
ppears to be stable. Although maternal body weight may  play a
ole in the aetiology of testicular cancer (Aschim et al., 2005) the
eason for this discrepancy remains unknown; however, there is
o evidence for a causal relation to chemical EDCs, to the con-
rary: for example, a large follow-up study in more than 1,300,000
anish man  found no correlation between testicular cancer and
eri-natal oestrogen exposure (Ramlau-Hansen et al., 2009). Sim-
larly, a review of 81 epidemiology publications concluded that
here is no strong epidemiological evidence to indicate that prenatal
xposure to oestrogen is linked to disturbed development of the male
eproductive organs (Storgaard et al., 2006). This notion is consistent
ith observations in a population of males that were exposed in
tero to maternal doses of DES, which observed no major increase
n the incidence of testicular cancer (Leary et al., 1984). Overall, it is
ncertain whether the TDS actually exists and even more uncertain
hat synthetic chemical EDCs are associated with it (Thorup et al.,
010; Safe, 2005).
. Personal care product ingredients: purported endocrine
isruptors?
A series of substances in personal care products have been
randed as putative EDC. They include solvents, such as diethyph-
halate, preservatives (long-chain parabens, triclosan), fragrances
polycyclic musks), UV ﬁlters (4-methylbenzylidene camphor) or
ong-chain phthalate esters (Witorsch and Thomas, 2010). It is true
hat certain long side-chain phthalates, such as diethylhexyl- or
utyl phthalates, have weak hormonal activities and may  affect
ale fertility in rats – when given at high oral doses. In con-
rast, diethylphthalate, which has been widely used as a vehicle
n fragrances, is devoid of hormonal activity or other signiﬁcant
oxicities. Diethylphthalate was shown to be non-toxic in a large
umber of safety evaluations and was rated to be safe for use in
osmetics by international expert groups, such as the EU SCCS or
he US Cosmetic Ingredient Review (Witorsch and Thomas, 2010).
owever, the chemical name phthalate made this substance target
f attacks by NGOs due to an alleged endocrine disrupting activity,
n other words: health risk assessment based on the name phthalate.tters 223 (2013) 295– 305
In 2001, the UV ﬁlter 4-methylbenzylidene camphor (4-MBC)
was reported to be active in vitro as well as in vivo (uterotrophic test
in immature female rats) screening studies for oestrogenic activity
(Schlumpf et al., 2001). However, when the substance was tested
under conditions of Good Laboratory Practice (GLP) in a complete
1-generation reproductive toxicity study, no adverse effects were
found (Broschard et al., 2004). Therefore, per deﬁnition, 4-MBC is
not an ED. In addition, an in-depth evaluation of the metabolism
of 4-MBC in humans and rats after dermal application as well as
a toxicokinetic-based safety assessment concluded that the sub-
stance poses no health risk for humans (Schauer et al., 2006).
Long side-chain parabens, such as butylparaben, but not methyl-
or ethylparaben, have also been reported to possess weak oestro-
genic activity in rats when given subcutaneously (but not when
given orally or dermally) at high doses (Routledge et al., 1998).
Other studies reported that repeated oral doses of butyl- and propy-
lparaben adversely affected male fertility parameters in juvenile
rats (Oishi, 2001). However, when the latter studies were repeated
in larger investigations and under conditions of Good Laboratory
Practice, no effect was  found at oral doses of up to 1000 mg/kg/day
suggesting that propyl- or butyl parabens have no ED activity (Gazin
et al., 2012; Hoberman et al., 2008).
In addition, it has been shown that whole-body application for
two weeks of a cream containing 2.0% butylparaben (10 times
the maximum concentration permitted in the EU and applied at
2 mg/cm2) did not affect reproductive and thyroid hormone lev-
els in humans (Janjua et al., 2007). A study in 332 consumers
(post-menopausal women) found no presence of butyl- or benzyl
parabens in their plasma (Sandanger et al., 2011). Subsequently, the
US Cosmetic Ingredient Review reviewed the safety of parabens
in-depth and concluded that all parabens are safe as used in
personal care products (CIR, 2008). In contrast, in the EU, the max-
imal content of propyl- and butylparabens in PCP were limited
to concentrations of 0.2%. In addition, there is growing evidence
that parabens, when used in products applied to the skin, are
hydrolysed (de-toxiﬁed) in human and animal skin resulting in
para-hydroxybenzoic acid (Jewell et al., 2007; Aubert et al., 2012;
CIR, 2008), a natural substance that is ubiquitous in plants, veg-
etables and human food. Para-hydroxybenzoic acid also occurs in
human breast milk at concentrations of approximately 600 g/kg,
whereas infant formulas contain up to 3590 g/kg (Li et al., 2009).
Taking into account that it is unlikely that the human organism
is systemically exposed to parabens after application of paraben-
containing PCP products to the skin, the potential human health risk
from parabens in PCPs should be rated negligible or absent. In this
context, it is interesting to note that methylparaben is a natural,
sex-attractant pheromone in female dogs (Goodwin et al., 1979).
Thus it may  be argued that, at least in canines, certain parabens
further reproduction rather than impede it.
5. Hormonal potency: a key topic of safety assessment
The key question on the safety of substances with a hormone-
like activity is their individual hormonal potency. The importance
of potency of potential EDC for their human and environmen-
tal safety assessment has been reviewed by several authors and
expert groups (Calabrese et al., 1997; Borgert et al., 2013; Fegert,
2013; Testai et al., 2013; Dietrich et al., 2013). To illustrate potency
aspects: both cyanide and table salt can be toxic, but cyanide is far
more potent than table salt. Consequently, using common sense or
risk management, people tend to be more cautious when they han-
dle cyanide than when they use table salt. In analogy, oestradiol, the
mammalian female sex hormone or synthetic oestrogens contained
in oral contraceptives are extremely potent and active in micro-
gram doses or when present in human blood at ng/mL levels, i.e. in
G.J. Nohynek et al. / Toxicology Letters 223 (2013) 295– 305 299
Table 1
Comparative oestrogenic potency of natural or synthetic substances in the rodent uterotrophic assay after oral doses (adapted from Golden et al., 2005; Nilsson, 2000;
Witorsch and Thomas, 2010).
Substance Use/Origin Effective dose (mg/kg/day) Relative potency
Diethylstilbestrol (DES) Drug 0.0001 3,000,000
Ethinylestradiol Contraceptive pill 0.0003 1,000,000
Estrone Human oestrogen 0.0012 250,000
Coumestrol Legumes (clover) 0.03 10,000
Genistein Soybeans 8 37
Daidzein Soybeans 12 25
4-MBC UV ﬁlter 300 1.0
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ivo. Indeed, natural or synthetic hormones (e.g. ethinylestradiol)
re 10,000 to 1,000,000-fold more potent than man-made chem-
cals with an oestrogenic activity, such as long-chain parabens or
ltraviolet ﬁlters (Golden et al., 2005; Witorsch, 2002a; Witorsch
nd Thomas, 2010; Table 1). These differences in potency are by
everal orders of magnitude higher than those between the toxic-
ty of table salt and cyanide. When imagining that one oestrogenic
otency unit corresponds to one horse power, ethinyl oestradiol
ingredient of the contraceptive pill) would have the power of a
uper tanker, coumestrol (clover) that of a bomber, genistein (soy
eans) that of a small car, whereas butyl- or benzylparaben would
e in the power range of that of a kitchen mixer or a children’s
icycle, respectively (Fig. 1).
Here it should be noted that butylparaben, although falsely
randed to be an “Endocrine Disrupter”, only showed extremely
eak potential for oestrogenic activity (rat uterotrophic test) when
dministered subcutaneously (injected under the skin) at doses of
00 mg/kg and higher (Routledge et al., 1998). This would corre-
pond to a human subcutaneous dose of 48 grams in a 60 kg human
eing in order to produce a potential activity (corresponding to
0 kg of a cream, containing 0.2% of butylparaben), not to mention
hat humans are less sensitive to some hormonal effects than rats
Borgert et al., 2012; Witorsch, 2002b)). When butylparaben was
iven orally to rats or applied to the skin of rats it had no oestrogenic
ig. 1. Assuming that one oestrogen potency unit (see Table 1) corresponds to one
orse power, the power/potency of some of the substances in Table 1 may  be ranked
s  follows.600 0.5
2500 0.12
activity (Routledge et al., 1998). In a reproductive study in young
male rats, butylparaben produced no adverse changes in repro-
ductive organs or reproductive hormone levels at doses exceeding
1000 mg/kg/day (Hoberman et al., 2008). Considering this, it is bio-
logically implausible how butylparaben, when included at 0.2% in
a cream, could have any effect at all or even pose a human health
risk. Overall, when taking into account their limited skin penetra-
tion, their metabolism in the skin and their minute oestrogenic
potency of substances used as cosmetic ingredients, a risk to human
health may  be excluded altogether (Golden et al., 2005; Witorsch
and Thomas, 2010). This view was  also supported by the results of
biomonitoring studies on actual blood levels of parabens in human
consumers. Given that detected levels were absent or negligible, a
hormonal effect, not to mention a human reproductive risk, may  be
clearly excluded (Sandanger et al., 2011). It has been argued that
the potency of the most active environmental oestrogens would
need to be at least 1000-times higher in order to present human
reproductive risks (Borgert et al., 2012).
Oestrogen-containing drugs (e.g. the contraceptive pill) or the
synthetic oestrogen DES possess potencies that are by 6 or 7 orders
of magnitude higher than that of long-chain parabens or UV ﬁl-
ters with “estrogenic activity” (Table 1; Fig. 1). Yet, prenatal in
utero exposure of men  to oestrogen drugs or DES did not adversely
affect their fertility (Hemminki et al., 1998; Wilcox et al., 1995;
Leary et al., 1984) or sperm parameters (Schumacher et al., 1981).
It is also noteworthy that DES, although it is several times more
potent than oestradiol, appears to have a no-effect level: human
in utero exposure to maternal doses of a total of 1.4 g DES over
101 days (approximately 0.25 mg/kg/day), a huge dose in terms
of oestrogenic potency, did not produce urogenital abnormalities
or abnormal sperm parameters in male offspring (Fish, 2000). A
no-effect level was  also observed for ethinyl oestradiol (an active
ingredient of the contraceptive pill): when injected in adult men
at high doses (60 g/day) it affected sperm motility and density; in
contrast, 20 g/day, still a huge dose in terms of hormonal potency,
had no effect on sperm motility and density (Lübbert et al., 1992).
Taking these data into account, the hypothesis that the negligible
exposure of humans to chemicals of negligible hormonal potency
could have an effect on human fertility is absurd defying a scientiﬁc
basis as well as common sense.
6. Health risks of simultaneous exposure to several
substances with weak hormone-like activities (“Cocktail
Effects”)
It has been hypothesised that, although individual man-made
substances generally have a very weak hormonal potency, the com-
bination of several weakly acting substances may  be additive or
even synergistic and thereby yet produce adverse effects on the
organism. This hypothesis has been raised as early as 1996 when
Arnold et al. (1996) claimed that mixtures of several chemicals had
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ynergistic potency on human oestrogen receptors. These data pro-
uced a major debate by the scientiﬁc community and the media
Anon., 1997). However, the results could not be reproduced in
ther laboratories because the data were fabricated, and the pre-
ious article was withdrawn by the authors (McLachlan, 1997).
ecently, the hypothesis of a possible addition or synergy of low
oses of EDs has been raised again (Vandenberg et al., 2012; Zoeller
t al., 2012). These, albeit hypothetical, effects were named Low-
ose Effects,  Dose Addition of substances that produce Common
dverse Outcomes (DA-CAOS) or Cocktail Effects.
However, these effects are highly improbable, if not impossi-
le, on the basis of theoretical as well as practical considerations
Borgert et al., 2005, 2012; Rhomberg and Goodman, 2012). First
f all, there is clear evidence that reproductive toxins includ-
ng those with a hormone-mediated mechanism have a threshold
f adversity (Piersma et al., 2011). To be additive, they would
ave to possess exactly the same mode of action (Borgert et al.,
005). Moreover, there is a multitude of direct or indirect mech-
nisms by which substances may  affect hormones or produce a
ormone-like activity. For example, substances that produce an
estrogen-like effect may  have an afﬁnity for cellular oestrogen
eceptors or oestrogen sub-receptors; they may  have agonistic or
ntagonistic properties, they may  have oestrogenic, androgenic
r anti-androgenic activity or they may  produce indirect effects,
uch as direct toxicity to, or stimulation/inhibition of oestrogen-
enerating tissues. Even when the same target organ or hormonal
ystem is affected, the mode of action of adversity may  be quite dif-
erent: for example, in rats, there are a multitude of mechanisms
hereby substances may  affect the thyroid or thyroid hormone lev-
ls, although many of these mechanisms are not relevant for man.
n addition, it has been recognised that the rat is an inadequate
odel to predict adverse effects on thyroid hormones of drugs in
an  (Wu  and Farelly, 2006).
In the organism there are many different hormones that may  act
n different receptors or sub-receptors. To illustrate this, not even
he natural oestrogen oestradiol and the powerful synthetic oestro-
en DES share an identical mode of action (Safe, 1998). Even after
imultaneous uptake of different substances that have the same or a
imilar mode of action, the possibility of additive or cocktail effects
s reduced by different absorption, metabolism and kinetic path-
ays, which are never identical for different substances. Moreover,
here are major quantitative and qualitative differences in the afﬁn-
ty or activity between weak and strong ligands (substances with
fﬁnity to cell receptors) to or on cell receptors. Based on phar-
acological principles, weak ligands will only occupy and trigger
ell receptors when present at high, near-toxic concentrations, but
hey have no effect when present at small concentrations. Over-
ll, the presence of myriads of weak hormone receptor agonists or
ntagonists in the environment and food is not expected to achieve
hysiological signiﬁcance, since many would be competitive ago-
ists/antagonists their low potencies would preclude activity via
he receptor (Borgert et al., 2005, 2012).
The complexity of these interactions has been demonstrated in
 number of studies. For example, at high concentrations (EC25
o EC50) a mixture of different-, anti-androgenic phthalates and
isphenol A had additive androgenic effects on MDA-kb2 cells,
hereas low concentration mixtures (<EC25) had antagonistic
ctivity (Christen et al., 2012). Despite the fact that different mix-
ure ratios near the observable response range can be interpreted
s concentration additive, there is no evidence of additivity at
oses in the range humans might be exposed, and no theoretical
ustiﬁcation for extrapolating such data to human exposure lev-
ls (Borgert et al., 2012). A similar phenomenon was conﬁrmed
n another study on mixtures of weakly estrogenic UV ﬁlters in
sh: mixtures containing high concentrations (EC10 to EC30) of
ndividual UV ﬁlters showed additive activity, whereas mixturestters 223 (2013) 295– 305
containing low concentrations (range: NOEC to EC05) had a lower
activity than predicted by the dose addition model, which sug-
gests antagonism (Kunz and Fent, 2009). No additive effects were
observed in rats after oral administration of combinations of high
doses of ethinylestradiol (a powerful oestrogen contained in con-
traceptive pills), and genistein, an oestrogenic isoﬂavone contained
in soy (Takagi et al., 2004). An additive effect was observed when
high doses of genistein were combined with therapeutic doses of
ethinylestradiol, whereas low doses showed no additivity (Charles
et al., 2007). This observation suggests that additivity may  be con-
strained to substances with moderate to high potency when given
near their individual response level, and would be unlikely to occur
with substances possessing low potency or when given at low doses
(Borgert et al., 2012). Since human exposures are typically orders
of magnitude below the observable response range, most mixture
studies are not relevant to human health risks.
No evidence of synergy was found when weakly estrogenic
hydroxylated polychlorinated biphenyls and pesticides were tested
in combination (Arcaro et al., 1998). Another large study inves-
tigated binary mixtures of six “endocrine disrupting” chemicals
(organochlorine compounds, phytoestrogens and actual hor-
mones) that were administered at ﬁve different concentrations
to bobwhite quail; some combinations were additive, others
were antagonistic. Although group sizes were low and therefore,
conclusions uncertain, no indications for synergy were detected
(McMurry and Dickerson, 2001).
Another study investigated oestrogenic responses to mixtures
of synthetic chemicals combined with phytoestrogens at various
dose levels. As would be predicted by theoretical pharmacologi-
cal considerations, low concentrations of the synthetic chemical
mixtures failed to increase in vitro or in vivo estrogenic responses
relative to phytoestrogens alone. Signiﬁcantly increased responses
occurred only when each synthetic chemical in the mixture was
near or above its individual response threshold. In vitro, high doses
of chemicals and phytoestrogens produced greater than additive
responses, whereas mixtures of synthetic chemicals produced less
than additive responses in the absence of phytoestrogens. In vivo,
the combined effects were consistent with additivity. The study
concluded that mixture effects are likely to be of concern only
when mixture components are present at or near their individual
response thresholds, and that extrapolation of mixture effects from
in vitro to in vivo should be approached with caution (Charles et al.,
2007).
Similarly, in another study, rat uterotrophic tests on a num-
ber of mixtures of synthetic chemicals (nonylphenol, octylphenol,
-hexachlorocyclohexane, methoxychlor, bisphenol A, dibutylph-
thalate) in combination with estradiol showed no additive or
synergistic effects, whereas some combinations of phytoestrogens
(coumestrol, genistein, narigenin, catechin, epicatechin, quercetin)
with estradiol acted additively. Interestingly, all synthetic chemi-
cals, when tested alone were inactive in the rat uterotrophic test
even at high dose levels relative to human exposure (Van Meeuven
et al., 2007).
The results of 90 different studies on endocrine effects of chem-
ical mixtures were recently reviewed by an expert group who
concluded that synergy is extremely rare and that the amount of
synergy at low doses, when occurring, did not exceed the levels
predicted by additive models by more than a factor of four (Boobis
et al., 2011).
Overall, there is no genuine in vivo evidence for additive or cock-
tail effects of small doses of man-made, chemical substances with
hormonal activity. Taking into account the fact that animals and
humans are exposed to thousands of natural hormone-like sub-
stances in their food and environment that are capable of overt
hormone-related toxicity at high levels of exposure in vitro, it is dif-
ﬁcult to explain how these species have survived if such substances
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igniﬁcantly add to or subtract from endogenous hormonal activity,
hich is vital for life (Borgert et al., 2012).
. Discussion: facts versus fears
Labels like “Endocrine disruptor” or “hormone-like substances”
re stigmatic terms; they sound dangerous, raise media attention
nd provoke human fears. Yet, in the absence of relevant human
xposure and potency data, these terms are meaningless in terms
f human health risks. Overall, the entire discussion whether man-
ade chemicals with hormone-like activity may  pose a risk to
uman health has a paradoxical aspect: if such activities, how-
ver small, could actually pose a potential health risk, then it
ould make sense to worry about all substances that possess such
ctivities, particularly when potent oestrogens, such as the contra-
eptive pill, are taken orally or when they are present in human
ood, such as phytoestrogens. To the contrary, a number of epi-
emiology studies suggest that the potent contraceptive pill or
aturally occurring soy isoﬂavones or other phytoestrogens, pose
o or negligible risk to human health or that of human progeny.
hus, it is difﬁcult to conceive how synthetic substances that are
ot eaten and possess only a tiny fraction of the activity of phar-
aceutical or some natural substances could be dangerous (see
ig. 1). Here it should be considered that average humans consume
bout 100 g of oestrogen equivalents a day from natural sources
e.g. soy ﬂavonoids), whereas chemicals, such as butylphthalate,
n human food amount to about 0.02 g oestrogen equivalents
Nilsson, 2000). Yet, activists and opportunistic and media-cited
cientists focus on that tiny number. To put these ﬁgures into per-
pective: a single contraceptive pill contains the staggering amount
f about 17,000 g of oestrogen equivalents, reﬂecting the striking
otency of genuine hormones.
Science is about establishing cause and effect, it is not about
uessing. Scientists develop a hypothesis – substance x causes
bservation y - and then should rigorously test the hypothesis to
etermine whether it is valid or not. If the hypothesis is tested rig-
rously and cannot be refuted, it must be tentatively accepted that
he hypothesis may  be right (Taubes, 2012). On the other hand, if
epeated testing fails to generate unequivocal support, the hypoth-
sis should be viewed with scepticism. Let us put the man-made
nvironmental disruptor hypothesis to the test: the hypothesis
as now been evaluated experimentally and epidemiologically for
early 20 years and no convincing evidence has been found of an
ctual decline in human fertility, and even less of a causal relation
ith synthetic hormonally active substances.
This raises another important issue: epidemiology attempts to
etermine the cause(s) of an established disease (Susser, 1991).
acteria, viruses or exposure to toxic substances may  cause human
iseases. To illustrate this, in the 1950s, a causal relation was estab-
ished for lung cancer and tobacco smoking. Indeed, lung cancer is
 genuine disease with measurable frequency. Its incidence dra-
atically increased in the 50s, whereas cigarette smoking became
ncreasingly popular in the preceding decades. Exposure was cer-
ain, given that tobacco smoke is directly inhaled into the lungs.
hus the hypothesis for a causal relation made biological sense and
ausality was conﬁrmed by a number of subsequent investigations
hat involved millions of subjects unequivocally exposed to direct
nhalation of tobacco smoke. But how can one determine a cause
f a disease when the existence of the disease itself is uncertain?
or example, the Testicular dysgenesis syndrome (TDS) is merely a
ypothetical disease, in other words: nobody knows whether this
isease exists or not - some experts in the ﬁeld doubt whether TDS
xists at all (Thorup et al., 2010). Scientiﬁcally and philosophically,
he search for a hypothetical cause of a hypothetical disease makes
o sense – would it not make more sense to ﬁrst make sure thattters 223 (2013) 295– 305 301
the disease actually exists, before spending millions on the quest
of its cause? With good reason, the quest for environmental, man-
made ED has rightly been titled by the European Molecular Biology
Organisation as A Cause without a Disease (Breithaupt, 2004). Never-
theless, we are now witnessing the advent of a massive regulatory
programme in search of a justiﬁable public health purpose (Gori,
2007). Finally, even when a substance is active in an in vitro or
in vivo ED assay, it is generally very difﬁcult to prove that the effect
was actually caused by an endocrine mechanism, since a concomi-
tant effect on endocrine function on its own  is not proof of causality
per se. As an example, many substances may  affect the rat thyroid
and rat thyroid hormones by a number of diverse modes of action
many of which are not endocrine-relevant (Wu and Farelly, 2006).
This poses an additional, yet unresolved, problem of how to prove
that a substance is an ED in actual practice.
The hypothesis of and subsequent search for man-made (syn-
thetic), chemical EDs in the environment, food or personal care
products began in the early 1990s. Up to date, this research has
spent hundreds of millions of Euros or Dollars of tax payer’s money.
In the EU alone, more than 150 million Euros have been spent on
research into potential health risks of EDCs (Jensen and van Vliet,
2012). Given this large amount of research funding there may also
be a vested interest of scientists in the ED ﬁeld to keep the ED
hypothesis on the agenda in order to stay in business.
In January 2013, a search in TOXLINE for the term “endocrine dis-
ruptors” yielded 4278 different articles (TOXLINE, 2013) reﬂecting
the enormous amount of scientiﬁc research devoted to this topic.
A search in MEDLINE for the term “endocrine disruption” listed
33 annual publications in 1992 with an increase to 290 in 2011
(MEDLINE, 2013). Taking into account the large resources spent
on this topic, one should expect that, in the meantime, some EDs
that cause actual human injury or disease should have been iden-
tiﬁed. However, this is not the case. To date, with the exception of
natural or synthetic hormones, not a single, man-made chemical
ED has been identiﬁed that poses an identiﬁable, measurable risk
to human health (the adverse effects of iatrogenic DES were long
known before the term endocrine disruptor was  coined). Certainly,
there has been much media hype about imaginary health risks from
bisphenol A, parabens or phthalates. However, no actual evidence
of adverse human health effects from these substances has ever
been established. To the contrary, there is increasing evidence that
their health risks are absent or negligible – or imaginary. It is inter-
esting to note that even substances, such as long-chain phthalates,
which were conﬁrmed to be EDs (anti-androgenic) in the rat, were
largely inactive in the mouse or in vivo ex situ human foetal testis
(Johnson et al., 2012). Given that the human foetus appears to be at
least an order of magnitude less sensitive to DES-induced reproduc-
tive tract malformations than the rat foetus (Borgert et al., 2012),
such species differences raise doubt as to the relevance of current
rat in vivo test data for humans who, in addition, are exposed envi-
ronmentally to far lower levels of such substances than laboratory
rats.
The largest human experiment on endocrine disruption
included more than a billion women and has continued for almost
half a century: the contraceptive pill. However, the contraceptive
pill does no signiﬁcant harm to human health, although it has
a powerful oestrogenic activity, is taken daily and is used over
long periods of time. It has been estimated that about 500 Mil-
lion women in the EU and the US annually use oral contraceptives
with approximately 5% or 25 million women per year becom-
ing pregnant and unknowingly expose their foetuses to potent
oestrogenic and progestin drugs (Takeda, 2001). Yet, no adverse
effects were observed in men  or women  after previous in utero
exposure to oestrogen-containing drugs (Hemminki et al., 1998;
Storgaard et al., 2006). The contraceptive pill is a genuine Endocrine
Disruptor: it affects human reproductive physiology and contains
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estradiols (natural or synthetic) that are toxic to reproduction
hen given at high doses. Human urinary excretion of residues of
he contraceptive pill as well as natural human and animal oestro-
ens in water may  also affect the environment and are thought
o be responsible for the feminisation of male ﬁsh that has been
bserved in large rivers downstream the efﬂuent water of major
ities or mass production of farm animals (Vajda et al., 2011; Jobling
t al., 2006). Interestingly, the contraceptive pill has rarely, if ever,
een a target of the EDC-lobby. It is outside the scope of this paper
o speculate about the reasons. Possibly, focusing on chemicals, and
ot pharmaceuticals provides the emotional argument that these
re everywhere and everybody is exposed or attacking the compar-
tively tiny oestrogenic activity of some chemicals that produce no
r negligible human exposure may  be more politically acceptable
han blaming the pill. Chemical substances are, after all, perceived
o pose a human and environmental health risk, whether this is
upported by scientiﬁc facts or not. Blaming the contraceptive pill
or adverse environmental effects is certainly less opportune.
It is not surprising that, when it was realised that it is implausible
hat hormonally active chemicals pose a human health risk given
he small human exposure and their negligible potencies, new
ypotheses had to be invented in support of the notion that they
ose a risk anyway, such as the Dose Addition of substances that pro-
uce Common Adverse Outcomes (DA-CAOS) (Kortenkamp and Faust,
010) or Cocktail Effects (Vandenberg et al., 2012). Despite of heroic
fforts to ﬁnd in vivo observational validation for these hypotheses,
he in vivo evidence continues to accumulate that these effects are
bsent at low doses/concentrations, which is consistent with phar-
acological theory (Borgert et al., 2012; Rhomberg and Goodman,
012). Another interesting hypothesis is the non-monotonic dose-
elationship, which postulates that, for EDs, high-dose effects may
e non-predictive for effects observed for low doses (Vandenberg
t al., 2012; Myers et al., 2009). Although this hypothesis is con-
istent with the ideas of homoeopathy, it contradicts centuries of
oxicological and pharmacological experience demonstrating that
ctive substances produce a speciﬁc dose-response in the affected
rganism. There are some exceptions to this rule, although they
re generally due to different mechanisms of the respective sub-
tance, such as hypervitaminosis A versus vitamin A deﬁciency,
oth of which can be teratogenic. Although non-monotonic dose
esponse curves for hormonal effects had been postulated in a
imited number of studies, the data could not be reproduced in
arger in vivo studies that included adequate quality assurance
Dekant and Colnot, 2013; Dietrich et al., 2013). Here an inter-
sting point may  be raised: if non-monotonic dose-relationships
ere relevant to the safety assessment of man-made, chemical EDs,
urely the same concept should also apply to the contraceptive pill
r phytoestrogens: accordingly, could a single Chinese meal or a
up of coffee wreak havoc with our endocrine systems? Does this
ssumption appear realistic?
In our view, the EDC saga may  be a political, rather than a sci-
ntiﬁc problem. Paradoxically, today soy oestrogens (isoﬂavones)
re marketed in health food stores with the claim that they
elieve menopausal symptoms. Yet, women in menopause have an
ncreased risk of breast cancer, whereas isoﬂavones have a potential
o promote mammary and endometrial carcinogenesis (Kakehashi
t al., 2012). Soy-phytoestrogens have also been reported to inhibit
he activity of anti-cancer drugs, which may  be of particular con-
ern for women with oestrogen-dependent breast cancer (Gallo
t al., 2007). In rats, in utero exposure to high maternal doses of the
oy phytoestrogens genistein has been shown to adversely affect
eproductive parameters in their male and female offspring; thus
oy isoﬂavones are genuine EDs (McClain et al., 2007; Delclos et al.,
001). At dietary levels, however, phytoestrogens do not appear to
nduce oestrogenic effects on the uterus of humans or non-human
rimates (Cline et al., 2001). Another interesting example of antters 223 (2013) 295– 305
endocrine-active substance is caffeine: caffeine was embryo- and
foeto-toxic in rat reproduction and developmental toxicity stud-
ies, it affected sperm quality in mice, increased the incidence of
tumours in endocrine organs (pituitary adenomas and mammary
tumours in mice and rats), and was positive in an in vitro steroido-
genesis assay. In addition, the margin of exposure for human coffee
consumers (mean daily intake: 240 mg  caffeine) relative to adverse
effects observed in animals is as low as 15- to 35-fold (Bars et al.,
2012). Very recently, another series of substances (vitamins C, B9,
B6, B3, sucrose, caffeine, gingerol, xanthane gum, paracetamol and
ibuprofen) were tested in a series of in vitro assays for endocrine
activity. Paracetamol, gingerol, caffeine and vitamin C affected
stereoidogenesis in vitro from 250, 25, 500 and 750 M, respec-
tively. Caffeine, when tested in vivo (rat pubertal assay) at dose
levels relevant for human consumption affected vaginal opening,
oestrus cycle and ovarian weight in females as well as plasma pro-
gesterone levels, prostate and seminal weights in males (Tinwell
et al., 2013). Surely, by today’s standards, caffeine would perfectly
qualify as a genuine ED at dose levels relevant to human exposure.
Today, a huge number of cellular and nuclear receptors and sub-
receptors are known, many of which respond to hormones. For
example, the International Union on Basic and Clinical Pharmacol-
ogy (IUPHAR) has established a database that includes 3500 ligand
classes (IUPHAR, 2013). Taking into account the ubiquitous pres-
ence of hormones in the organism and their role in its regulation
on a cellular level (OECD DRP, 2012; Godman and Gilman, 2011),
one could ask a provocative question: would not most substances,
when administered at doses sufﬁciently high to affect a target organ
ultimately display an endocrine disrupting potential somewhere in
the organism? For example, it is known that table salt intake and
subsequent changes in sodium plasma concentrations may  affect
renal hormones with subsequent effect on blood pressure (Isozaki
et al., 1995). Table salt may  also interact with the activity of oral
contraceptives (Pechère-Bertschi et al., 2003). Water intake may
affect human adrenal, renal and hepatic hormones, such as aldos-
terone, renin or angiotensin levels (Testai et al., 2013). Would this
make table salt or water potential EDs? In other words, the majority
of known substances could possibly be classiﬁed as potential EDs
when tested in depth. Yet, would such a classiﬁcation contribute to
a human health beneﬁt?
Paradoxically, our society and its regulators appear to be quite
tolerant towards potent substances that are conﬁrmed EDs and
are taken orally by a large number of humans. These examples
show how the focus on purported man-made, endocrine disrupting
chemicals (EDCs) distracts from potential health risks of human
exposure to other substances with far greater potential for hor-
monal activity. Perhaps the entire issue of purported health risks of
chemical EDs is just another version of the trivial dichotomy natural
is good versus man-made is bad.
Finally, when reﬂecting on the presence of all these man-made,
albeit hypothetical, EDCs in the environment, why should EDCs
primarily affect the male sex, such as a potential decline in male fer-
tility, a hypothetical increase in the incidence of hypospadias and
cryptorchidism in male babies, increase in the incidence of male tes-
ticular cancers, a reduced penis length in male alligators (Guilette
et al., 1996), or cause feminisation of male ﬁsh? Why  should females
be less affected? Are females less susceptible and, if so, why? On the
other hand, could there be a male sex-bias concerning these imag-
inary risks? Recently, it has been claimed that boys from mothers
with higher phthalate levels in their urine showed a reduced ten-
dency for masculine play behaviour, such a preference of toys over
masculine play. Interestingly, girls seemed unaffected by mater-
nal phthalate levels (Swan et al., 2009). True or not, mothers may
rather be relieved about reduced masculine play behaviour of their
sons. However, some fathers would probably be more concerned
about such data: my boy showing un-masculine, i.e. feminised play
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ehaviour? Would not terms, such as feminisation of males, reduced
enis length and size or a declining male fertility mainly strike male
maginations and sensitivities – and, after all, most researchers in
he ﬁeld of EDCs and, more importantly, politicians handing our
esearch funds are men. Could this be a coincidence? One may  won-
er whether the entire issue of EDC is more within the competence
f Dr. Sigmund Freud than that of toxicology.
Overall, it appears weird how the supporters of the ED hypoth-
sis appear to be mesmerised by the idea that a handful of weakly
cting chemicals that involve produce little or negligible human
xposure must be somehow responsible for a range of hypotheti-
al adverse effects on human reproduction or other human health
roblems. About 150 years ago, Alexandre Dumas coined the phrase
herchez la femme! - meaning that, in every human crime, there
s always a woman involved who plays a key role [Translation of
he complete phrase: There is a woman in every case; as soon as
hey bring me a report, I say, ‘Look for the woman!’ (Dumas, 1871)].
oday, this view may  strike us as somewhat naïve and sexist. In
ontrast, today’s popular belief rather appears to be: cherchez le
roduit chimique! (Translation: look for the chemical!)  - expressing
he belief that, in every human health problem, man-made, syn-
hetic chemicals must play a key role. Would this not be equally
aïve?
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